186 search results for: Pathophysiology
ADVENT On Air Podcast: Unmet Needs and Current Treatment Landscape
In this podcast, Dr. Teri Greiling and Dr. Daniel Butler discuss the enormous burden patients with bullous pemphigoid experience and how our understanding of the disease pathophysiology may help address unmet treatment needs.
Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis
Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.
World Congress of Dermatology (WCD) 2023 | Singapore
Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Bullous Pemphigoid: Insights and Innovation
Watch Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap at EADV 2025 as they explore the clinical presentation and diagnosis of BP and break down the underlying pathophysiology including the roles of autoimmunity and key inflammatory pathways such as Type 2 inflammation. The experts also discuss the evolving therapeutic landscape and how new insights are shaping future treatment strategies.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
ADVENT On Air | Role of Type 2 Inflammation in COPD
Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Exploring the Mechanisms of FeNO Production in the Lungs
Explore how type 2 inflammation drives the production of FeNO in severe asthma
